The increase in abdominal subcutaneous fat depot is an independent factor to determine the glycemic control after rosiglitazone treatment

European Journal of Endocrinology

Volumn 157, Issue 2, 2007, Pages 167-174

  Kim, Soo Kyung ^a,b   Hur, Kyu Yeon ^b   Kim, Hae Jin ^c   Shim, Wan Sub ^b   Ahn, Chul Woo ^b   Park, Seok Won ^a   Cho, Yong Wook ^a   Lim, Sung Kil ^b   Lee, Hyun Chul ^b   Cha, Bong Soo ^b  

^a CHA University   (South Korea)

^b Yonsei University College of Medicine   (South Korea)

^c Ajou University School of Medicine   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; GLUCOSE; HEMOGLOBIN A1C; ROSIGLITAZONE;

ABDOMINAL SUBCUTANEOUS FAT; ADULT; ARTICLE; BODY FAT DISTRIBUTION; BODY MASS; BODY WEIGHT; CLINICAL ASSESSMENT; CLINICAL TRIAL; CONTROLLED STUDY; DIET RESTRICTION; DRUG EFFICACY; ECHOGRAPHY; FEMALE; GLYCEMIC CONTROL; HUMAN; HYPOGLYCEMIA; INTRAABDOMINAL FAT; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; THICKNESS; TREATMENT DURATION; TREATMENT RESPONSE;

ABDOMINAL FAT; BLOOD GLUCOSE; BODY COMPOSITION; DIABETES MELLITUS, TYPE 2; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; LIPID METABOLISM; MALE; MIDDLE AGED; REGRESSION ANALYSIS; THIAZOLIDINEDIONES;

EID: 34547785470     PISSN: 08044643     EISSN: None     Source Type: Journal    
DOI: 10.1530/EJE-07-0043     Document Type: Article

References (35)

1. Taylor SI, Accili D & Imai Y. Insulin resistance or insulin deficiency. Which is the primary cause of NIDDM? Diabetes 1994 43 735-740.
2. Chaour M, Theroux P, Gilfix BM, Campeau L, Lesperance J, Ghitescu M, Gelinas F & Solymoss BC. True fasting serum insulin level, insulin resistance syndrome and coronary artery disease. Coronary Artery Disease 1997 8 683-688.
3. Nestler JE & Jakubowicz DJ. Lean women with polycystic ovary syndrome respond to insulin reduction with decreases in ovarian P450c17α activity and serum androgens. Journal of Clinical Endocrinology and Metabolism 1997 82 4075-4079.
4. Saltiel AR & Olefsky JM. Thiazolidinediones in the treatment of insulin resistance and type II diabetes. Diabetes 1996 45 1661-1669.
5. Maggs DG, Buchanan TA, Burant CF, Cline G, Gumbiner B, Hsueh WA, Inzucchi S, Kelley D, Nolan J, Olefsky IM, Polonsky KS, Silver D, Valiquett TR & Shulman GI. Metabolic effects of troglitazone monotherapy in type 2 diabetes mellitus. A randomized, double-blind, placebo-controlled trial. Annals of Internal Medicine 1998 128 176-185.
6. Mudaliar S & Henry RR. PPAR agonists in health and disease: a pathophysiologic and clinical overview. Current Opinion in Endocrinology, Diabetes and Obesity 2002 9 285-302.
7. Spiegelman BM. PPAR-γ: adipogenic regulator and thiazolidinedione receptor. Diabetes 1998 47 507-514.
8. Adams M, Montague CT, Prins JB, Holder JC, Smith SA, Sanders L, Digby JE, Sewter CP, Lazar MA, Chatterjee VK & O'Rahilly S. Activators of peroxisome proliferator-activated receptor gamma have depot-specific effects on human preadipocyte differentiation. Journal of Clinical Investigation 1997 100 3149-3153.
9. Okuno A, Tamemoto H, Tobe K, Ueki K, Mori Y, Iwamoto K, Umesono K, Akanuma Y, Fujiwara T, Horikoshi H, Yazaki Y & Kadowaki T. Troglitazone increases the number of small adipocytes without the change of white adipose tissue mass in obese Zucker rats. Journal of Clinical Investigation 1998 101 1354-1361.
10. Mori Y, Murakawa Y, Okada K, Horikoshi H, Yokoyama J, Tajima N & Ikeda Y. Effect of troglitazone on body fat distribution in type 2 diabetic patients. Diabetes Care 1999 22 908-912.
11. Miyazaki Y, Mahankali A, Matsuda M, Mahankali S, Hardies J, Cusi K, Mandarino LJ & DeFronzo RA. Effect of pioglitazone on abdominal fat distribution and insulin sensitivity in type 2 diabetic patients. Journal of Clinical Endocrinology and Metabolism 2002 87 2784-2791.
12. Carey DG, Cowin GJ, Galloway GJ, Jones NP, Richards JC, Biswas N & Doddrell DM. Effect of rosiglitazone on insulin sensitivity and body composition in type 2 diabetic patients. Obesity Research 2002 10 1008-1015.
13. Akazawa S, Sun F, Ito M, Kawasaki E & Eguchi K. Efficacy of troglitazone on body fat distribution in type 2 diabetes. Diabetes Care 2000 23 1067-1071.
14. Lukaski HC, Bolonchuk WW, Hall CB & Siders; WA. Validation of tetrapolar bioelectrical impedance method to assess human body composition. Journal of Applied Physiology 1986 60 1327-1332.
15. Suzuki R, Watanabe S, Hirai Y, Akiyama K, Nishide T, Matsushima Y, Murayama H, Ohshima H, Shinomiva M, Shirai K, Saito Y, Yoshida S, Saisho H & Ohto M. Abdominal wall fat index, estimated by ultrasonography, for assessment of the ratio of visceral fat to subcutaneous fat in the abdomen. American Journal of Medicine 1993 95 309-314.
16. Armellini F, Zamboni M, Rigo L, Bergamo-Andreis IA, Robbi R, DeMarchi M & Bosello O. Sonography detection of small intra-abdominal fat variations. International Journal of Obesity 1991 15 847-852.
17. Iozzo P, Hallsten K, Oikonen V, Virtanen KA, Parkkola R, Kemappainen J, Solin O, Lonnqvist F, Ferrannini E, Knuuti J & Nuutila P. Effects of metformin and rosiglitazone monotherapy on insulin-mediated hepatic glucose uptake and their relation to visceral fat in type 2 diabetes. Diabetes Care 2003 26 2069-2074.
18. Katoh S, Hata S, Matsushima M, Ikemoto S, Inoue Y, Yokoyama J & Tajima N. Troglitazone prevents the rise in visceral adiposity and improves fatty liver associated with sulfonylurea therapy - a randomized controlled trial. Metabolism 2001 50 414-417.
19. Fujioka S, Matsuzawa Y, Tokunaga K & Tauri S. Contribution of intra-abdominal fat accumulation to the impairment of glucose and lipid metabolism in human obesity. Metabolism 1987 36 54-59.
20. Virtanen KA, Hallsten K, Parkkola R, Janatuinen T, Lonnqvist F, Viljanen T, Ronnemaa T, Knuuti J, Huupponen R, Lonnroth P & Nuutila P. Differential effects of rosiglitazone and metformin on adipose tissue distribution and glucose uptake in type 2 diabetic subjects. Diabetes 2003 52 283-290.
21. Cnop M, Havel PJ, Utzschneider KM, Carr DB, Sinha MK, Boyko EJ, Retzlaff BM, Knopp RH, Brunzell JD & Kahn SE. Relationship of adiponectin to body fat distribution, insulin sensitivity and plasma lipoproteins: evidence for independent roles of age and sex. Diabetologia 2003 46 459-469.
22. Zamboni M, Zoico E, Fantin F, Panourgia MP, Di Francesco V, Tosoni P, Solerte B, Vetter R & Bosello O. Relation between leptin and the metabolic syndrome in elderly women. Journals of Gerontology. Series A, Biological Sciences and Medical Sciences 2004 59 396-400.
23. Fasshauer M & Paschke R. Regulation of adipocytokines and insulin resistance. Diabetalogia 2003 46 1594-1603.
24. Maruyama S, Yanagisawa K, Kanamuro R, Teno S & Iwamoto Y. Serum leptin level as an indicator to predict the clinical efficacy of troglitazone in patients with type 2 diabetes mellitus. Diabetes Research and Clinical Practice 2001 53 161-164.
25. Wu J, Lei MX, Chen HL & Sun ZX. Effects of rosiglitazone on serum leptin and insulin resistance in patients with type 2 diabetes. Zhong Nan Da Xue Xue Bao Yi Xue Ban 2004 29 623-626.
26. Hotta K, Funahashi T, Arita Y, Takahashi M, Matsuda M, Okamoto Y, Iwahashi H, Kuriyama H, Ouchi N, Maeda K, Nishida M, Kihara S, Sakai N, Nakajima T, Hasegawa K, Muraguchi M, Ohmoto Y, Nakamura T, Yamashita S, Hanafusa T & Matsuzawa Y. Plasma concentrations of a novel, adipose-specific protein, adiponectin, in type 2 diabetic patients. Arteriosclerosis, Thrombosis, and Vascular Biology 2000 20 1595-1599.
27. Ouchi N, Kihara S, Arita Y, Maeda K, Kuriyama H, Okamoto Y, Hotta K, Nishida M, Takahashi M, Nakamura T, Yamashita S, Funahashi T & Matsuzawa Y. Novel modulator for endothelial adhesion molecules: adipocyte-derived plasma protein adiponectin. Circulation 1999 100 2473-2476.
28. Yamauchi T, Kamon J, Waki H, Terauchi Y, Kubota N, Hara K, Mori Y, Ide T, Murakami K, Tsuboyama-Kasaoka N, Ezaki O, Akanuma. Y, Gavrilova O, Vinson C, Reitman ML, Kagechika H, Shudo K, Yoda M, Nakano Y, Tobe K, Nagai R, Kimura S, Tomita M, Froguel P & Kadowaki T. The fat-derived hormone adiponectin reverses insulin resistance associated with both lipoatrophy and obesity. Nature Medicine 2001 7 941-946.
29. Yang WS, Jeng CY, Wu TJ, Tanaka S, Funahashi T, Matsuzawa Y, Wang JP, Chen CL, Tai TY & Chuang LM. Synthetic peroxisome proliferator-activated receptor-gamma agonist, rosiglitazone, increases plasma levels of adiponectin in type 2 diabetic patients. Diabetes Care 2002 25 376-380.
30. Satoh N, Ogawa Y, Usui T, Tagami T, Kono S, Uesugi H, Sugiyama H, Sugawara A, Yamada K, Shimatsu A, Kuzuya H & Nakao K. Antiatherogenic effect of pioglitazone in type 2 diabetic patients irrespective of the responsiveness to its antidiabetic effect. Diabetes Care 2003 26 2493-2499.
31. Kuzuya T, Kosaka K, Akanuma Y & Kaneko T. Baseline factors affecting the efficacy of troglitazone on plasma glucose in Japanese patients with non-insulin-dependent-diabetes meilitus. Diabetes Research and Clinical Practice 1998 41 121-129.
32. Mohanty P, Aljada A, Ghanim H, Hofmeyer D, Tripathy D, Syed T, Al-Haddad W, Dhindsa S & Dandona P. Evidence for a potent antiinflammatory effect of rosiglitazone. Journal of Clinical Endocrinology and Metabolism 2004 89 2728-2735.
33. Rossner S, Bo WJ, Hiltbrandt E, Hinson W, Karstaedt N, Santago P, Sobol WT & Crouse JR. Adipose tissue determinations in cadavers - a comparison between cross-sectional planimetry and computed tomography. International Journal of Obesity and Related Metabolic Disorders 1990 14 893-902.
34. Ribeiro-Filho FF, Faria AN, Kohlmann O, Jr, Ajzen S, Ribeiro AB, Zanella MT & Ferreira SRG. Ultrasonography for the evaluation of visceral fat and cardiovascular risk. Hypertension 2001 38 713-717.
35. Kim SK, Kim HJ, Hur KY, Choi SH, Ahn CW, Lim SK, Kim KR, Lee HC & Cha BS. Visceral fat thickness measured by ultrasonography can estimate not only visceral obesity, but also risks of cardiovascular and metabolic diseases. American Journal of Clinical Nutrition 2004 79 593-599.